Reliable non-invasive biomarkers for endometriosis remain unavailable in routine practice, and their translational value depends on performance in symptomatic referral populations rather than only against healthy controls. We evaluated Nuclear …
Elagolix sodium salt is the first marketed orally active non-peptide gonadotropin-releasing hormone receptor antagonist (GnRHR-ant) for the management of hormone dependent diseases, such as endometriosis and uterine fibroids. Despite its …